Inhibition of canonical NF-κB activity by knockdown of dl or dif did not significantly suppress RAP tumour overgrowth in the presence of trametinib (compare Fig. 1H to 1I,J, quantified in 1K). The gene discussed is NFKB1; the disease is neoplasm.